Alnylam Pharmaceuticals, Inc. (ALNY)

Nasdaq Health Care Biotechnology Nasdaq-100

$155.94

-0.72 (-0.46%)

Close of Nov 06, 2026 · end-of-day data

Source: Alnylam Pharmaceuticals, Inc.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$47.16M	$89.91M	$74.91M	$219.75M	$492.85M	$844.29M	$1.04B	$1.83B	$2.25B	$3.71B
Cost of revenue	—	$0	$1.80M	$25.06M	$74.19M	$115.00M	$140.17M	$268.22M	$306.51M	$677.17M
Gross profit	—	$89.91M	$73.11M	$194.69M	$418.67M	$729.28M	$897.24M	$1.56B	$1.94B	$3.04B
Research & development	$382.39M	$390.63M	$505.42M	$655.11M	$654.82M	$792.16M	$883.01M	$1.00B	$1.13B	$1.32B
Selling, general & admin	$89.35M	$199.37M	$382.36M	$479.00M	$588.42M	$620.64M	$770.66M	$795.65M	$975.53M	$1.21B
Operating income	-$424.59M	-$500.09M	-$814.67M	-$939.43M	-$828.44M	-$708.65M	-$785.07M	-$282.18M	-$176.88M	$501.58M
Interest expense	—	—	$0	$0	$84.50M	$143.02M	$155.97M	$121.22M	$141.86M	$252.63M
Pre-tax income	-$410.11M	-$490.87M	-$760.67M	-$885.25M	-$855.60M	-$852.14M	-$1.13B	-$433.52M	-$377.38M	$323.15M
Income tax	$0	$0	$823.00K	$863.00K	$2.68M	$680.00K	$4.16M	$6.72M	-$99.22M	$9.40M
Net income	-$410.11M	-$490.87M	-$761.50M	-$886.12M	-$858.28M	-$852.82M	-$1.13B	-$440.24M	-$278.16M	$313.75M
EBITDA	-$409.46M	-$486.72M	-$799.42M	-$922.26M	-$793.67M	-$661.09M	-$740.60M	-$228.12M	-$120.22M	$557.24M
EPS (basic)	$-4.79	$-5.42	$-7.57	$-8.11	$-7.46	$-7.20	$-9.30	$-3.52	$-2.18	$2.39
EPS (diluted)	$-4.79	$-5.42	$-7.57	$-8.11	$-7.46	$-7.20	$-9.30	$-3.52	$-2.18	$2.33
Diluted shares	85.60M	90.55M	100.59M	109.26M	114.99M	118.45M	121.69M	124.91M	127.65M	134.68M
Gross margin	—	100.0%	97.6%	88.6%	84.9%	86.4%	86.5%	85.3%	86.4%	81.8%
Operating margin	-900.3%	-556.2%	-1087.6%	-427.5%	-168.1%	-83.9%	-75.7%	-15.4%	-7.9%	13.5%
Net margin	-869.6%	-545.9%	-1016.6%	-403.2%	-174.1%	-101.0%	-109.0%	-24.1%	-12.4%	8.4%

Balance sheet

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$193.62M	$645.36M	$420.15M	$547.18M	$496.58M	$819.98M	$866.39M	$812.69M	$966.43M	$1.66B
Short-term investments	$424.19M	$1.05B	$662.80M	$975.02M	$1.33B	$1.55B	$1.30B	$1.62B	$1.72B	$1.25B
Receivables	$23.33M	$34.00M	$18.76M	$43.01M	$102.41M	$198.57M	$237.96M	$327.79M	$405.31M	$777.57M
Inventory	—	—	$24.07M	$56.35M	$75.20M	$86.36M	$128.96M	$89.15M	$78.51M	$82.72M
Total current assets	$671.88M	$1.76B	$1.20B	$1.72B	$2.61B	$2.81B	$2.69B	$2.98B	$3.30B	$4.05B
Total assets	$1.26B	$1.99B	$1.57B	$2.40B	$3.41B	$3.64B	$3.55B	$3.83B	$4.24B	$4.97B
Total current liabilities	$131.70M	$144.25M	$179.49M	$352.59M	$585.27M	$695.71M	$767.91M	$967.79M	$1.19B	$1.47B
Long-term debt	—	—	—	—	$191.28M	$675.70M	—	—	—	—
Total debt	—	—	—	—	$191.28M	$675.70M	—	—	—	—
Total liabilities	$342.59M	$228.30M	$272.84M	$956.44M	$2.39B	$3.06B	$3.70B	$4.05B	$4.17B	$4.18B
Shareholders' equity	$920.22M	$1.77B	$1.30B	$1.44B	$1.02B	$588.20M	-$158.22M	-$220.64M	$67.09M	$789.18M

Cash flow

fiscal years · USD

Fiscal year	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$307.70M	-$382.79M	-$562.62M	-$278.43M	-$614.96M	-$641.69M	-$541.27M	$104.16M	-$8.31M	$524.08M
Capital expenditures	$64.56M	$104.21M	$126.89M	$140.16M	$70.36M	$76.37M	$72.06M	$62.21M	$34.28M	$58.70M
Free cash flow	-$372.26M	-$487.00M	-$689.50M	-$418.58M	-$685.32M	-$718.07M	-$613.33M	$41.95M	-$42.59M	$465.38M
Investing cash flow	$142.59M	-$290.36M	$272.94M	-$417.68M	-$435.52M	-$273.30M	$169.35M	-$336.35M	-$116.84M	$436.33M
Financing cash flow	$177.83M	$1.12B	$65.47M	$823.18M	$994.98M	$1.25B	$425.75M	$172.13M	$294.16M	-$305.19M
Stock-based compensation	$75.53M	$92.82M	$157.75M	$174.84M	$139.87M	$165.72M	$230.65M	$221.68M	$272.08M	$348.24M
Depreciation & amortization	$15.13M	$13.37M	$15.25M	$17.18M	$34.77M	$47.57M	$44.47M	$54.05M	$56.67M	$55.66M

Income statement

quarters · USD

Quarter ended	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Jun 2026	Sep 2026
Revenue	$750.53M	$439.72M	$494.33M	$659.83M	$500.92M	$593.17M	$594.19M	$773.69M	$1.25B	$1.10B	$1.29B	$1.46B
Cost of revenue	$79.47M	$71.97M	$54.61M	$67.27M	$81.98M	$102.65M	$70.18M	$142.03M	$197.23M	$267.72M	$298.26M	$361.75M
Gross profit	$671.06M	$367.74M	$439.72M	$592.55M	$418.94M	$490.52M	$524.01M	$631.66M	$1.05B	$829.31M	$992.69M	$1.10B
Research & development	$253.18M	$272.14M	$261.00M	$294.14M	$270.93M	$300.17M	$265.12M	$323.62M	$358.81M	$372.22M	$413.13M	$408.54M
Selling, general & admin	$199.18M	$198.12M	$210.80M	$248.40M	$220.99M	$295.34M	$239.95M	$323.31M	$322.08M	$325.37M	$347.92M	$342.00M
Operating income	$213.87M	-$116.40M	-$43.44M	$48.61M	-$76.91M	-$105.16M	$18.08M	-$16.20M	$367.98M	$131.72M	$231.44M	$345.80M
Interest expense	$30.89M	$31.34M	$35.25M	$33.26M	$34.38M	$38.97M	$58.31M	$61.46M	$67.46M	$65.40M	$82.05M	$84.37M
Pre-tax income	$150.74M	-$137.69M	-$63.59M	-$11.17M	-$108.66M	-$193.96M	-$2.37M	-$41.31M	$280.57M	$86.26M	$177.81M	$295.81M
Income tax	$2.99M	$183.00K	$2.35M	$5.72M	$2.91M	-$110.19M	$15.88M	$30.92M	-$12.12M	-$25.28M	$13.31M	-$1.87B
Net income	$147.75M	-$137.87M	-$65.94M	-$16.89M	-$111.57M	-$83.76M	-$18.25M	-$72.23M	$292.68M	$111.54M	$164.49M	$2.17B
EBITDA	$227.19M	-$102.92M	-$29.92M	$63.62M	-$62.92M	-$90.99M	$32.48M	-$2.25M	$381.79M	$145.22M	—	$360.27M
EPS (basic)	$1.18	$-1.09	$-0.52	$-0.13	$-0.87	$-0.65	$-0.14	$-0.55	$2.23	$0.84	$1.23	$16.19
EPS (diluted)	$1.15	$-1.09	$-0.52	$-0.13	$-0.87	$-0.65	$-0.14	$-0.55	$2.14	$0.82	$1.21	$15.72
Diluted shares	131.34M	239.00K	126.14M	126.73M	128.59M	492.00K	129.68M	130.63M	137.35M	538.00K	138.28M	138.04M
Gross margin	89.4%	83.6%	89.0%	89.8%	83.6%	82.7%	88.2%	81.6%	84.2%	75.6%	76.9%	75.2%
Operating margin	28.5%	-26.5%	-8.8%	7.4%	-15.4%	-17.7%	3.0%	-2.1%	29.5%	12.0%	17.9%	23.7%
Net margin	19.7%	-31.4%	-13.3%	-2.6%	-22.3%	-14.1%	-3.1%	-9.3%	23.4%	10.2%	12.7%	148.6%

Balance sheet

quarters · USD

Quarter ended	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Jun 2026	Sep 2026
Cash & equivalents	$1.03B	$812.69M	$681.88M	$968.49M	$1.10B	$966.43M	$1.02B	$1.11B	$1.49B	$1.66B	$1.71B	$1.75B
Short-term investments	$1.36B	$1.62B	$1.68B	$1.65B	$1.67B	$1.72B	$1.61B	$1.74B	$1.23B	$1.25B	$1.60B	$1.83B
Receivables	$325.44M	$327.79M	$321.38M	$309.48M	$353.85M	$405.31M	$418.04M	$567.11M	$964.77M	$777.57M	$912.74M	$1.08B
Inventory	$95.77M	$89.15M	$93.99M	$83.98M	$75.99M	$78.51M	$65.58M	$71.69M	$75.38M	$82.72M	$97.11M	$105.91M
Total current assets	$2.99B	$2.98B	$2.99B	$3.17B	$3.36B	$3.30B	$3.27B	$3.64B	$3.95B	$4.05B	$4.62B	$5.11B
Total assets	$3.84B	$3.83B	$3.82B	$4.01B	$4.21B	$4.24B	$4.21B	$4.57B	$4.85B	$4.97B	$5.56B	$7.99B
Total current liabilities	$949.78M	$967.79M	$941.71M	$1.06B	$1.22B	$1.19B	$1.08B	$1.30B	$1.56B	$1.47B	$1.51B	$2.06B
Total liabilities	$4.00B	$4.05B	$4.04B	$4.01B	$4.17B	$4.17B	$4.10B	$4.32B	$4.62B	$4.18B	$4.20B	$4.39B
Shareholders' equity	-$165.87M	-$220.64M	-$219.27M	-$3.07M	$32.35M	$67.09M	$426.14M	$555.35M	$580.25M	$789.18M	$1.35B	$3.60B

Cash flow

quarters · USD

Quarter ended	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Jun 2026	Sep 2026
Operating cash flow	$359.41M	-$29.80M	-$81.52M	$124.16M	$43.71M	-$94.66M	-$118.31M	$127.81M	$296.86M	$217.73M	—	$340.99M
Capital expenditures	$17.09M	$15.31M	$12.97M	$8.02M	$4.19M	$9.09M	$8.97M	$14.29M	$12.14M	$23.29M	—	$69.83M
Free cash flow	$342.32M	-$45.10M	-$94.49M	$116.14M	$39.52M	-$103.76M	-$127.28M	$113.52M	$284.71M	$194.44M	—	$271.15M
Investing cash flow	-$10.76M	-$240.66M	-$67.62M	$33.94M	-$30.25M	-$52.91M	$113.77M	-$141.38M	$501.11M	-$37.17M	—	-$311.74M
Financing cash flow	$33.14M	$39.23M	$28.91M	$131.50M	$102.75M	$31.00M	$44.08M	$79.68M	-$420.09M	-$8.86M	—	$18.35M
Stock-based compensation	$63.94M	$41.99M	$45.35M	$89.29M	$45.80M	$91.64M	$56.71M	$111.68M	$108.21M	$71.63M	$86.62M	$79.12M
Depreciation & amortization	$13.33M	$13.48M	$13.52M	$15.00M	$13.98M	$14.17M	$14.40M	$13.94M	$13.80M	$13.51M	—	$14.48M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.